Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
| Brand name | DULOXETINE |
| Generic name | DULOXETINE HYDROCHLORIDE |
| Active ingredient(s) | DULOXETINE HYDROCHLORIDE |
| Distributed by / for | Breckenridge Pharmaceutical, Inc. Berkeley Heights, NJ 07922 |
| NDC | 51991-748-10 |
| Full product label | Duloxetine Delayed-Release Capsules USP, 60 mg, 1000-count bottles, Rx Only, Manufactured by Towa Pharmaceutical Europe, S.L., Distributed by Breckenridge Pharmaceutical, Inc. Berkeley Heights, NJ 07922, NDC# 51991-748-10 |
| Recalling firm | Breckenridge Pharmaceutical, Inc |
| Distribution | US Nationwide. |
| Quantity | 16,473 bottles |
| Recall initiated | 2025-04-14 |
| Report date | 2025-04-30 |
| Recall completed | — |
| Recall number | D-0387-2025 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Berlin CT United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗